Rufinamide: a new antiepileptic drug treatment for Lennox–Gastaut syndrome

Ferrie, Colin D.

doi:10.1586/ern.10.51

Cited by 11 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 588 publications were excluded because they did not meet the inclusion criteria. The seven remaining publications were off‐topic or duplicates of studies in the Cochrane review . Thus, no articles from the literature search were included in this systematic review.…”

Section: Resultsmentioning

confidence: 99%

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Cramer

Sapin²,

François³

2013

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Cramer

Sapin²,

François³

2013

Acta Neurol Scand

View full text Add to dashboard Cite

show abstract

“…As phenobarbital is a common antiepileptic used in canine patients, investigation into the impact phenobarbital has on the pharmacokinetics of rufinamide in dogs is warranted. While impaired renal function has not been shown to affect rufinamide pharmacokinetics in humans, the impact hepatic insufficiency may have is not known (Ferrie, 2010). Studies are required to determine how concurrent liver or kidney disease might alter the pharmacokinetics of rufinamide.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of oral rufinamide in dogs

Wright¹,

Chen²,

Martinez³

et al. 2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

The objective of this study was to determine the pharmacokinetic properties and short-term adverse effect profile of single-dose oral rufinamide in healthy dogs. Six healthy adult dogs were included in the study. The pharmacokinetics of rufinamide were calculated following administration of a single mean oral dose of 20.0 mg/kg (range 18.6-20.8 mg/kg). Plasma rufinamide concentrations were determined using high-performance liquid chromatography, and pharmacokinetic data were analyzed using commercial software. No adverse effects were observed. The mean terminal half-life was 9.86 ± 4.77 h. The mean maximum plasma concentration was 19.6 ± 5.8 μg/mL, and the mean time to maximum plasma concentration was 9.33 ± 4.68 h. Mean clearance was 1.45 ± 0.70 L/h. The area under the curve (to infinity) was 411 ± 176 μg · h/mL. Results of this study suggest that rufinamide given orally at 20 mg/kg every 12 h in healthy dogs should result in a plasma concentration and half-life sufficient to achieve the therapeutic level extrapolated from humans without short-term adverse effects. Further investigation into the efficacy and long-term safety of rufinamide in the treatment of canine epilepsy is warranted.

show abstract

“…The bioavailability of RUF is probably less than 85% and protein binding, primarily to albumin, is relatively low and ranges from 26 to 34%. 5 The t½ of RUF is approximately 6 to 10 hours. 6 RUF is metabolized primarily by carboxylesterases to an inactive metabolite (CGP 47292) and is excreted renally.…”

Section: Introductionmentioning

confidence: 99%

“…4,7 Several studies have suggested that enzyme-inducing AEDs (EIAEDs) can increase the clearance and decrease the concentration of RUF. 4,5,7 The primary aim of this study was to examine the influence of age and type of concomitant AEDs on the clearance of RUF and to examine the influence of RUF on the clearance of concomitant AEDs in children with epilepsy. The secondary aim was to evaluate the efficacy and adverse events of RUF in the study group.…”

Section: Introductionmentioning

confidence: 99%

Rufinamide in Children with Refractory Epilepsy: Pharmacokinetics, Efficacy, and Safety

Dahlin

Öhman

2012

Neuropediatrics

View full text Add to dashboard Cite

We examined the influence of age and type of concomitant antiepileptic drugs (AEDs) on the pharmacokinetics of rufinamide (RUF) as well as its efficacy and safety in 51 children with refractory epilepsy. In a retrospective noninterventional survey, dose-to-concentration ratios of RUF and concomitant AEDs were calculated: the weight-normalized dose (mg/kg/d) divided by the steady-state trough plasma drug level, which was used as a measure of clearance. During treatment with RUF concomitantly with valproic acid (VPA) young children, aged 0 to 4.9 years, had a low clearance of RUF, which did not differ from older children. If not on VPA but on enzyme inducers, young children had a threefold higher clearance of RUF than the older ones. In young children not on VPA, those on enzyme inducers had 1.7-fold higher clearance than those on nonenzyme inducers. In children neither on VPA nor on enzyme inducers, RUF clearance was age-dependent with higher clearance in younger children. Adding RUF did not change the pharmacokinetics of concomitantly used AEDs. Seizure response after 2 to 3 months on RUF treatment was found in 12 of 51 children (23.5%), at mean plasma level of 36.9 ± 22.0 µmol/L. Adverse events were reported in 41% of the patients of which fatigue was most frequent (24%).

show abstract

Rufinamide: a new antiepileptic drug treatment for Lennox–Gastaut syndrome

Cited by 11 publications

References 26 publications

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome

Pharmacokinetics of oral rufinamide in dogs

Rufinamide in Children with Refractory Epilepsy: Pharmacokinetics, Efficacy, and Safety

Contact Info

Product

Resources

About